What is Circa Bioscience?
Circa Bioscience, LLC is a bioengineering firm specializing in the creation of innovative diagnostic, screening, and monitoring technologies. The company's core focus lies in identifying and validating disease-relevant biomarkers, with a particular emphasis on conditions such as autism spectrum disorder (ASD). Their proprietary technologies are engineered for versatile application across clinical settings, laboratories, and home-based use, aiming to significantly enhance the understanding and management of complex diseases through precise biomarker measurement.
How much funding has Circa Bioscience raised?
Circa Bioscience has raised a total of $18K across 1 funding round:
Debt
$18K
Debt (2021): $18K with participation from PPP
Key Investors in Circa Bioscience
PPP
Public-Private Partnership
What's next for Circa Bioscience?
Operating within a Series A/B growth stage, Circa Bioscience is poised for significant expansion. The recent capital injection is expected to fuel advancements in their biomarker validation pipeline and the scaling of their diagnostic technologies. Strategic investments will likely target enhancing their market penetration in the neurodevelopmental and metabolic disease sectors, potentially leading to new partnerships and broader clinical adoption of their innovative solutions.
See full Circa Bioscience company page
